Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (10012)	10/29/2008 5:17:41 PM
From: Qualified Opinion	Read Replies (1) \| Respond to of 10345

I guess it depends on ones forecast of additional cases of PML being reported. If so, it might be worth a look as a speculative buy.

To: tom pope who wrote (10012)	10/29/2008 6:47:29 PM
From: IRWIN JAMES FRANKEL	Read Replies (2) \| Respond to of 10345

>> Is this case within the expected bounds? My intuitive reaction is that we are still well below the label. Any statisticians want to comment? The 14 month term strikes me as modal. Hasn't that number come up before? If so, that may even be good. Do patients who get past Scylla and Charybdis have a lower risk? Or will we find that risk increases with time on drug? Any of the medical wizzes care to inform this lawyer? ij